Help protect patients who have DKD* and T2D

INVOKANA® 100 mg: the first SGLT2i proven
to slow the progression of DKD1

INVOKANA® 100 mg: the first SGLT2i proven to slow the progression of DKD1

INVOKANA® reduced the relative risk of the primary composite outcome of end-stage kidney disease,† doubling of serum creatinine, and renal‡ or CV death1

Chart showing the effect INVOKANA had on D K D in the CREDENCE trial

The landmark CREDENCE trial ended early after the overall risks and benefits were assessed and clear evidence of efficacy was shown.1

Patients were already taking a maximum tolerated dose of an ACEi or ARB.1

  • N=4401
  • Mean duration of diabetes: 15.8 years
  • Mean baseline eGFR: 56.2 mL/min/1.73 m2
  • Median baseline urinary albumin-to-creatinine ratio: 927 mg/g
See the CREDENCE trial safety results

eGFR is measured in mL/min/1.73 m2.
*With albuminuria >300 mg/day.
†End-stage kidney disease was defined as dialysis for ≥30 days, kidney transplantation, or an eGFR <15 mL/min/1.73 m2 sustained for ≥30 days.
‡There were not enough events to evaluate the risk of renal death (placebo, n=5; INVOKANA®, n=2). INVOKANA® is not indicated to reduce the risk of renal death.

ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CREDENCE=Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; CV=cardiovascular; DKD=diabetic kidney disease; HR=hazard ratio; RRR=relative risk reduction; SGLT2i=sodium-glucose co-transporter 2 inhibitor; T2D=type 2 diabetes.

Perkovic et al

CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) was a randomized, double-blind, placebo-controlled, parallel group, multicenter, event-driven clinical trial. The trial compared the effects of INVOKANA® 100 mg vs placebo in 4401 men and women with type 2 diabetes and diabetic kidney disease (described as chronic kidney disease with eGFR 30 to <90 mL/min/1.73 m2 and albuminuria [ratio of albumin to creatinine >300 to 5000 mg/g]) who were already taking a stable, maximum-tolerated, or labeled dose (for ≥4 weeks prior to randomization) of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). The mean eGFR of patients was 56.2 mL/min/1.73 m2 and the median urinary albumin-to-creatinine ratio was 927 mg/g. The primary efficacy outcome was the composite of end-stage kidney disease (dialysis, transplant, or eGFR <15 mL/min/1.73 m2), doubling of serum creatinine, or renal or cardiovascular (CV) death. Prespecified secondary outcomes included a composite of CV death or hospitalization for heart failure; a composite of heart attack, stroke, or CV death; hospitalization for heart failure; and a composite of end-stage kidney disease, doubling of the serum creatinine level, or renal death.1